Developing Innovative High-Impact Therapeutic Solutions that Address Major Unmet Needs in Healthcare

Learn More

Orchestra BioMed is a Healthcare Innovation Company

Orchestra BioMed is a biomedical innovation company focused on developing high-impact therapeutic solutions to address significant unmet needs in cardiovascular health and other areas. We specialize in developing novel therapies that are:

  • Designed to fit current clinical treatment paradigms and leverage the established procedural techniques well-known to interventional physicians; and
  • Based on the use as well as convergence of advanced medical technology, biopharmaceuticals, biomaterials-based drug delivery, and intelligent bioelectronic therapeutic algorithms

Our business model is designed to advance promising therapeutic solutions through development and aims to leverage strategic partnerships with established global commercial leaders to optimize commercialization and profitability. The Orchestra BioMed team of industry leaders has proven expertise in every phase of medtech and biopharma product development. Our primary focus on cardiovascular disease reflects our goal to rapidly advance disruptive solutions that will improve the standard of care for millions of patients worldwide.

Product Pipeline Overview

Advancing a deep, multi-asset pipeline of high-impact therapeutic solutions built around two technology platforms.

Learn More

News & Events

Orchestra BioMed™ to Present at the Innovation in Cardiovascular Interventions Meeting and the CSI Focus D-HF Congress

December 5, 2019

New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced upcoming presentations at the Innovation in Cardiovascular Interventions (ICI) Meeting in Tel-Aviv, Israel, taking place December 8-10, 2019 and the CSI Focus D-HF Congress in Paris taking place December 13-14, 2019.

Orchestra BioMed™ to Present at the Canaccord Genuity MedTech and Diagnostics Forum and the 31st Annual Piper Jaffray Healthcare Conference

November 19, 2019

New Hope, PA – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced David P. Hochman, chairman, CEO and founder, will present at the Canaccord Genuity MedTech and Diagnostics Forum on November 21, 2019 and the 31st Annual Piper Jaffray Healthcare Conference on December 4, 2019.

Additional conference details can be found below:

Read All News